These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36609655)

  • 1. Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis.
    Jørgensen NT; Erichsen TM; Jørgensen MB; Idorn T; Feldt-Rasmussen B; Holst JJ; Feldt-Rasmussen U; Klose M
    Pituitary; 2023 Feb; 26(1):152-163. PubMed ID: 36609655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
    Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
    Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
    Dirksen C; Bojsen-Møller KN; Jørgensen NB; Jacobsen SH; Kristiansen VB; Naver LS; Hansen DL; Worm D; Holst JJ; Madsbad S
    Diabetologia; 2013 Dec; 56(12):2679-87. PubMed ID: 24048673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis.
    Aitken ML; Szkudlinska MA; Boyko EJ; Ng D; Utzschneider KM; Kahn SE
    Diabetologia; 2020 May; 63(5):1055-1065. PubMed ID: 31993716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
    Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.
    Cypryk K; Vilsbøll T; Nadel I; Smyczyńska J; Holst JJ; Lewiński A
    Gynecol Endocrinol; 2007 Jan; 23(1):58-62. PubMed ID: 17484514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of medical therapies for acromegaly on glucose metabolism.
    Urbani C; Sardella C; Calevro A; Rossi G; Scattina I; Lombardi M; Lupi I; Manetti L; Martino E; Bogazzi F
    Eur J Endocrinol; 2013 Jul; 169(1):99-108. PubMed ID: 23660641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
    Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
    Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
    Højberg PV; Vilsbøll T; Rabøl R; Knop FK; Bache M; Krarup T; Holst JJ; Madsbad S
    Diabetologia; 2009 Feb; 52(2):199-207. PubMed ID: 19037628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).
    Ranganath L; Schaper F; Gama R; Morgan L; Wright J; Teale D; Marks V
    Diabetes Metab Res Rev; 1999; 15(6):390-4. PubMed ID: 10634963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.